Patents by Inventor Daniel O'Malley
Daniel O'Malley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220306630Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.Type: ApplicationFiled: August 5, 2020Publication date: September 29, 2022Inventors: Lalgudi S. Harikrishnan, Peter Kinam Park, Zheming Ruan, Donna D. Wei, Daniel O'Malley, Honghe Wan, Ashok Vinayak Purandare, Brian E. Fink
-
Publication number: 20220289736Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.Type: ApplicationFiled: May 6, 2021Publication date: September 15, 2022Inventors: Gary D. Glick, Shomir Ghosh, William R. Roush, Edward James Olhava, Daniel O'Malley
-
Publication number: 20220257587Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: ApplicationFiled: April 28, 2022Publication date: August 18, 2022Inventors: Daniel O'Malley, Ashvinkumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
-
Publication number: 20220259090Abstract: Systems for producing articles from glass tube include a converter having a base with a plurality of processing stations and a turret moveable relative to the base. The turret indexes a plurality of holders for holding the glass tubes successively through the processing stations. The systems further include a gas flow system or a suction system for producing a flow of gas through the glass tube during one or more heating, forming, separating or piercing operations. The flow of gas through the glass tube produced by the gas flow system or suction system may be sufficient to evacuate or purge volatile constituents of the glass from the glass tube and/or pierce a meniscus formed on the glass tube during separation, thereby reducing the Surface Hydrolytic Response (SHR) of the interior surface of the glass tube and articles made therefrom.Type: ApplicationFiled: May 6, 2022Publication date: August 18, 2022Inventors: Lewis Kirk Klingensmith, Joseph Michael Matusick, Connor Thomas O'Malley, Matthew Daniel Trosa, Steven Robert Wagner
-
Patent number: 11344543Abstract: The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: GrantFiled: July 12, 2018Date of Patent: May 31, 2022Assignee: Innate Tumor Immunity, Inc.Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
-
Publication number: 20220089572Abstract: The present invention provides compounds of Formula (I):(I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: ApplicationFiled: January 13, 2020Publication date: March 24, 2022Inventors: Ashvinikumar V. Gavai, Derek J. Norris, Daniel O'MALLEY, Steven P. Seitz, Jay A. Markwalder, David K. Williams, Hua Gong, Scott Hunter Watterson, Christine M. Tarby
-
Publication number: 20220087991Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: ApplicationFiled: January 20, 2020Publication date: March 24, 2022Inventors: Scott Hunter Watterson, Daniel O'Malley, Ashvinikumar V. Gavai, Hua Gong, Christine M. Tarby
-
Publication number: 20220089566Abstract: The present invention provides compounds of Formula (I), (II) or (III): (I), (II), (III), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: ApplicationFiled: January 20, 2020Publication date: March 24, 2022Inventors: SCOTT HUNTER WATTERSON, Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Steven P. Seitz, Hua Gong
-
Publication number: 20220089571Abstract: The present invention provides compounds of Formula (I): Formula (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: ApplicationFiled: January 13, 2020Publication date: March 24, 2022Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Derek J. Norris, Hua Gong, Yong Zhang, Patrice Gill, Christine M. Tarby, Matthias Broekema, Scott Hunter Watterson
-
Publication number: 20210365428Abstract: Systems and methods are provided for integrated data analysis. At least one object that is responsive to a first search query is determined. The object is stored in an object model that is managed by a first computing platform, and the at least one object is associated with one or more properties. One or more data sets that are responsive to a second search query are determined. The data sets are managed by a second computing platform. The one or more data sets are determined related to the at least one object. The at least one object is updated to include at least one property that references at least one analysis that relies on the one or more data sets.Type: ApplicationFiled: August 5, 2021Publication date: November 25, 2021Inventors: Alexander Mark, Andrew Elder, Caitlin Colgrove, Daniel O'Malley, Hannah Korus, Michael Barone, Sharon Hao, William Rhyne
-
Patent number: 11100079Abstract: Systems and methods are provided for integrated data analysis. At least one object that is responsive to a first search query is determined. The object is stored in an object model that is managed by a first computing platform, and the at least one object is associated with one or more properties. One or more data sets that are responsive to a second search query are determined. The data sets are managed by a second computing platform. The one or more data sets are determined related to the at least one object. The at least one object is updated to include at least one property that references at least one analysis that relies on the one or more data sets.Type: GrantFiled: March 28, 2019Date of Patent: August 24, 2021Assignee: Palantir Technologies Inc.Inventors: Alexander Mark, Andrew Elder, Caitlin Colgrove, Daniel O'Malley, Hannah Korus, Michael Barone, Sharon Hao, William Rhyne
-
Patent number: 10783162Abstract: Systems, methods, and non-transitory computer readable media may provide workflow assistance for performing operations on information. Information defining a graph may be accessed and a set of operations for the graph may be provided. The graph may represent objects with nodes and connections among the objects with edges. A user's selection of one or more operations from the set of operations may be received. A workflow of operations for the graph may be generated based on the user's selection. The workflow of operations may include the operation(s) selected by the user.Type: GrantFiled: January 22, 2018Date of Patent: September 22, 2020Assignee: Palantir Technologies Inc.Inventors: David Montague, Brandon Marc-Aurele, Clare Adrien, Eric Jeney, Daniel O'Malley, Vincent Tilson
-
Publication number: 20200157096Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.Type: ApplicationFiled: November 25, 2019Publication date: May 21, 2020Inventors: Gary D. Glick, Shomir Ghosh, William R. Roush, Edward James Olhava, Daniel O'Malley
-
Publication number: 20200129500Abstract: The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: ApplicationFiled: July 12, 2018Publication date: April 30, 2020Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
-
Patent number: 10533005Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.Type: GrantFiled: February 16, 2018Date of Patent: January 14, 2020Assignee: Innate Tumor Immunity, Inc.Inventors: Gary Glick, Shomir Ghosh, William R. Roush, Edward James Olhava, Daniel O'Malley
-
Publication number: 20190220455Abstract: Systems and methods are provided for integrated data analysis. At least one object that is responsive to a first search query is determined. The object is stored in an object model that is managed by a first computing platform, and the at least one object is associated with one or more properties. One or more data sets that are responsive to a second search query are determined. The data sets are managed by a second computing platform. The one or more data sets are determined related to the at least one object. The at least one object is updated to include at least one property that references at least one analysis that relies on the one or more data sets.Type: ApplicationFiled: March 28, 2019Publication date: July 18, 2019Inventors: Alexander Mark, Andrew Elder, Caitlin Colgrove, Daniel O'Malley, Hannah Korus, Michael Barone, Sharon Hao, William Rhyne
-
Patent number: 10289711Abstract: Systems and methods are provided for integrated data analysis. At least one object that is responsive to a first search query is determined. The object is stored in an object model that is managed by a first computing platform, and the at least one object is associated with one or more properties. One or more data sets that are responsive to a second search query are determined. The data sets are managed by a second computing platform. The one or more data sets are determined related to the at least one object. The at least one object is updated to include at least one property that references at least one analysis that relies on the one or more data sets.Type: GrantFiled: March 30, 2017Date of Patent: May 14, 2019Assignee: Palantir Technologies Inc.Inventors: Alexander Mark, Andrew Elder, Caitlin Colgrove, Daniel O'Malley, Hannah Korus, Michael Barone, Sharon Hao, William Rhyne
-
Publication number: 20190055236Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.Type: ApplicationFiled: February 16, 2018Publication date: February 21, 2019Inventors: Gary Glick, Shomir Ghosh, William R. Roush, Edward James Olhava, Daniel O'Malley
-
Patent number: 10196387Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.Type: GrantFiled: February 13, 2017Date of Patent: February 5, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Michael A. Poss, David R. Tortolani, Ashok Vinayak Purandare, John S. Tokarski, Christopher P. Mussari, Muthoni G. Kamau, Dharmpal S. Dodd, Ashvinikumar V. Gavai, Daniel O'Malley, Tram N. Huynh, Wayne Vaccaro, Lalgudi S. Harikrishnan
-
Patent number: 10053454Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: February 27, 2014Date of Patent: August 21, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Michael A. Poss, David R. Tortolani, Ashok Vinayak Purandare, John S. Tokarski, Christopher P. Mussari, Muthoni G. Kamau, Dharmpal S. Dodd, Ashvinikumar V. Gavai, Daniel O'Malley, Tram N. Huynh, Wayne Vaccaro, Lalgudi S. Harikrishnan